These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8893134)

  • 1. Comment: HMG-CoA reductase inhibitor-induced impotence.
    Boyd IW
    Ann Pharmacother; 1996 Oct; 30(10):1199. PubMed ID: 8893134
    [No Abstract]   [Full Text] [Related]  

  • 2. HMG-CoA reductase inhibitor-induced impotence.
    Halkin A; Lossos IS; Mevorach D
    Ann Pharmacother; 1996 Feb; 30(2):192. PubMed ID: 8835058
    [No Abstract]   [Full Text] [Related]  

  • 3. [HMG-CoA reductase inhibitors and sexual dysfunction].
    Pía Iglesias G; Fernández Fernández FJ; Ameneiros Lago E; Sesma Sánchez P
    An Med Interna; 2001 Mar; 18(3):171. PubMed ID: 11594194
    [No Abstract]   [Full Text] [Related]  

  • 4. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems.
    Carvajal A; Macias D; Sáinz M; Ortega S; Martín Arias LH; Velasco A; Bagheri H; Lapeyre-Mestre M; Montastruc JL
    Drug Saf; 2006; 29(2):143-9. PubMed ID: 16454541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase].
    Martinez-García FA; Martín-Fernández J; Moltó JM; Villaverde R; Morales A; Fernández-Barreiro A
    Rev Neurol; 1997 Jun; 25(142):869-71. PubMed ID: 9244616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Headache relief or impotence?
    Benjamin N
    Lancet; 1999 Jan; 353(9149):256-7. PubMed ID: 9929015
    [No Abstract]   [Full Text] [Related]  

  • 8. HMG-CoA reductase inhibitors in organ transplantation.
    Motomura N; Saito S; Foegh ML
    J Nephrol; 1997; 10(2):68-76. PubMed ID: 9238613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver function testing in patients on HMG-CoA reductase inhibitors.
    Andrade SE; Donahue JG; Chan KA; Watson DJ; Platt R
    Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):307-13. PubMed ID: 12812011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
    Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
    Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.
    Golomb BA; Evans MA
    Med J Aust; 2007 Aug; 187(4):253. PubMed ID: 17708735
    [No Abstract]   [Full Text] [Related]  

  • 12. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated enzyme inhibition assay method for the determination of atorvastatin-derived HMG-CoA reductase inhibitors in human plasma using radioactivity detection.
    Valesky RJ; Liu L; Musson DG; Zhao JJ
    J Pharmacol Toxicol Methods; 2008; 57(1):61-9. PubMed ID: 17651990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
    Nakashima A; Nakashima R; Ito T; Masaki T; Yorioka N
    Diabet Med; 2004 Sep; 21(9):1020-4. PubMed ID: 15317608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Schistosoma mansoni 3-hydroxymethylglutaryl-coenzyme-A reductase has different inhibitor kinetics compared to the mammalian host enzyme.
    El-Meanawy A; Hammd H; Chen GZ; Rottman F; Bennett JL
    Trop Gastroenterol; 2005; 26(3):132-5. PubMed ID: 16512462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
    Johnston TP; Palmer WK
    Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of rosuvastatin and atorvastatin on erectile dysfunction in hypercholesterolaemic patients.
    Nurkalem Z; Yildirimtürk Ö; Özcan KS; Kul Ş; Çanga Y; Satılmış S; Bozbeyoğlu E; Kaya C
    Kardiol Pol; 2014; 72(3):275-9. PubMed ID: 24142756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin-induced lactic acidosis: a rare adverse reaction?
    Goli AK; Goli SA; Byrd RP; Roy TM
    Clin Pharmacol Ther; 2002 Oct; 72(4):461-4. PubMed ID: 12386648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
    Keller RK; Zhao Z; Chambers C; Ness GC
    Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
    Massay RJ; Maynard AA
    West Indian Med J; 2012 Oct; 61(7):743-5. PubMed ID: 23620974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.